HUP0101895A2 - Biológiailag lebontható, tartós felszabadulású alginát gélek - Google Patents

Biológiailag lebontható, tartós felszabadulású alginát gélek

Info

Publication number
HUP0101895A2
HUP0101895A2 HU0101895A HUP0101895A HUP0101895A2 HU P0101895 A2 HUP0101895 A2 HU P0101895A2 HU 0101895 A HU0101895 A HU 0101895A HU P0101895 A HUP0101895 A HU P0101895A HU P0101895 A2 HUP0101895 A2 HU P0101895A2
Authority
HU
Hungary
Prior art keywords
hydrogels
alginate ester
alginate gels
biodegradable sustained
sustained release
Prior art date
Application number
HU0101895A
Other languages
English (en)
Inventor
Merrill Seymour Goldenberg
Jian Hua Gu
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of HUP0101895A2 publication Critical patent/HUP0101895A2/hu
Publication of HUP0101895A3 publication Critical patent/HUP0101895A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A találmány tárgyát biológiailag lebomló, biokompatibilispoliszacharid hidrogélek új osztálya, azaz például az alginát észterhidrogélek képezik terápiás hatású fehérjék tartós felszabadulásánakbiztosításához. Az alginát észter hidrogélek váratlan módon, amellett,hogy a módosítatlan alginátok gélesedési, injekciózhatósági és tartósfelszabadulást biztosító tulajdonságaival rendelkeznek, nem okoznakdudort az injekciózás helyén, azaz, az alginát észter hidrogélekbiológiailag lebomlanak, vagy elkopnak, és fokozatosan felszívódnak akörnyező szövetekbe, nagyon csekély reakciót okozva az injekciózáshelyén. Ó
HU0101895A 1998-05-18 1999-05-14 Biodegradable sustained-release alginate gels HUP0101895A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/080,832 US6432449B1 (en) 1998-05-18 1998-05-18 Biodegradable sustained-release alginate gels
PCT/US1999/010737 WO1999059549A1 (en) 1998-05-18 1999-05-14 Biodegradable sustained-release alginate gels

Publications (2)

Publication Number Publication Date
HUP0101895A2 true HUP0101895A2 (hu) 2001-10-28
HUP0101895A3 HUP0101895A3 (en) 2004-01-28

Family

ID=22159900

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101895A HUP0101895A3 (en) 1998-05-18 1999-05-14 Biodegradable sustained-release alginate gels

Country Status (25)

Country Link
US (2) US6432449B1 (hu)
EP (1) EP1079811B1 (hu)
JP (1) JP2002515419A (hu)
KR (1) KR20010025023A (hu)
CN (1) CN1309556A (hu)
AT (1) ATE343378T1 (hu)
AU (1) AU3993999A (hu)
BG (1) BG65397B1 (hu)
BR (1) BR9910553A (hu)
CA (1) CA2331446C (hu)
CY (1) CY1105944T1 (hu)
DE (1) DE69933763T2 (hu)
DK (1) DK1079811T3 (hu)
EA (1) EA003670B1 (hu)
ES (1) ES2275341T3 (hu)
HU (1) HUP0101895A3 (hu)
IL (1) IL139617A0 (hu)
NO (1) NO20005564L (hu)
NZ (1) NZ507943A (hu)
PL (1) PL199499B1 (hu)
PT (1) PT1079811E (hu)
RS (1) RS49841B (hu)
SK (1) SK16752000A3 (hu)
WO (1) WO1999059549A1 (hu)
ZA (1) ZA200006299B (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007673A1 (en) * 1999-11-12 2001-07-12 Merrill Seymour Goldenberg Sustained-release delayed gels
KR100426636B1 (ko) * 2001-05-18 2004-04-08 한국과학기술연구원 주사 가능한 젤 상의 조성물 및 그의 제조방법
WO2002100425A1 (en) * 2001-06-11 2002-12-19 Ltt Institute Co., Ltd. Aggregate composition for sustained-release preparation, process for producing the same, and sustained-release preparation containing the same
AU2003205106A1 (en) * 2002-01-16 2003-09-02 Agency For Disease Diagnosis And Prevention Pace-a microspheres for delivery of antigens
US6592852B1 (en) * 2002-04-25 2003-07-15 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Zinc citrate beads in oral compositions
KR100523953B1 (ko) * 2002-08-27 2005-10-25 주식회사 엘지생명과학 천연다당류와 히알루론산의 마이크로비드 및 이의 제조 방법
KR100507545B1 (ko) * 2002-09-03 2005-08-09 주식회사 엘지생명과학 히알루론산 유도체 및 그의 제조방법
JP4459543B2 (ja) 2003-03-17 2010-04-28 株式会社メドジェル 徐放性ハイドロゲル製剤
SI1682184T1 (sl) * 2003-11-04 2014-02-28 Lek Pharmaceuticals D.D. Stabilen farmacevtski sestavek, obsegajoč faktor za stimulacijo kolonije granulocitov
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
EP1803464A4 (en) * 2004-09-17 2009-09-09 Cellgentech Inc TOPICAL PREPARATION FOR THE TREATMENT OF SKIN DISEASES
CA2583373C (en) * 2004-10-12 2013-09-03 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
US9119901B2 (en) 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US8663686B2 (en) * 2005-05-09 2014-03-04 University Of Washington Biodegradable chitosan-PEG compositions and methods of use
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
US20080085295A1 (en) * 2006-07-14 2008-04-10 Fmc Biopolymer As Hydrogels containing low molecular weight alginates and biostructures made therefrom
DE102007039871A1 (de) * 2007-08-21 2009-02-26 Friedrich-Baur-Gmbh Weichgewebe-Implantat mit antibakterieller Wirkung
CN103463638A (zh) * 2007-08-28 2013-12-25 Fmc有限公司 延迟的自胶凝藻酸盐体系及其应用
ES2327375B1 (es) 2007-11-14 2010-08-05 Universidad Del Pais Vasco Empleo de microparticulas para su uso como vacunas y la liberacion de moleculas biologicamente activas.
US20090183503A1 (en) * 2008-01-18 2009-07-23 Alberto Verdesi Exhaust apparatus
US20100015240A1 (en) * 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
US9446168B2 (en) 2010-06-07 2016-09-20 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
WO2010032242A1 (en) * 2008-09-17 2010-03-25 Beta O2 Technologies Ltd. Optimization of alginate encapsulation of islets for transplantation
CA2780274C (en) 2009-11-09 2018-06-26 Spotlight Technology Partners Llc Fragmented hydrogels
CA2780294C (en) 2009-11-09 2018-01-16 Spotlight Technology Partners Llc Polysaccharide based hydrogels
US20130149349A1 (en) * 2010-06-03 2013-06-13 Indiana University Research And Technology Corporation Use of compounds with thrombopoietic activity to promote bone growth and healing
WO2012005783A1 (en) 2010-07-09 2012-01-12 Board Of Regents Of The University Of Texas System Biodegradable scaffolds
CR20160147A (es) 2011-03-25 2016-08-03 Amgen Inc Formulaciones de anticuerpos
CN102489027B (zh) * 2011-12-12 2014-06-04 山东凯翔生物化工有限公司 一种葡萄糖酸内酯节能浓缩方法及装置
CN103830266A (zh) * 2013-04-24 2014-06-04 杨亚勤 部分氧化海藻酸钠羧甲基化衍生物的制备方法和应用
RU2548777C2 (ru) * 2013-07-09 2015-04-20 Александр Александрович Кролевец Способ получения частиц инкапсулированных жирорастворимой полимерной оболочкой солей металлов, обладающих супрамолекулярными свойствами
US10611850B2 (en) 2014-07-14 2020-04-07 Amgen Inc. Crystalline antibody formulations
AU2015289874A1 (en) 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
CA2995372C (en) * 2015-08-13 2023-10-24 Northeastern University Biomaterials for combined radiotherapy and immunotherapy of cancer
EP3501553A1 (en) * 2017-12-21 2019-06-26 Association for the Advancement of Tissue Engineering and Cell based Technologies & Therapies (A4TEC) - Associação Hydrogel comprising manganese, methods and uses thereof
CN109293138A (zh) * 2018-10-08 2019-02-01 曹布道 一种养殖污水净化处理方法
WO2020254179A1 (en) 2019-06-21 2020-12-24 Alfasigma S.P.A. Pharmaceutical compositions in the form of gel containing xyloglucan and alcohols for the controlled release of active ingredients
CN112426981B (zh) * 2020-11-30 2021-12-28 西安交通大学 一种金属离子交联水凝胶及制备方法和应用
CN114685778B (zh) * 2020-12-30 2023-10-17 苏州艾博生物科技有限公司 长循环阳离子脂质体的合成方法
CN112843328B (zh) * 2021-02-25 2022-05-13 山东大学 一种具有抑菌作用的鲍鱼壳粉/ZnO复合材料掺杂的智能水凝胶伤口敷料的制备方法
CN114539442A (zh) * 2022-04-02 2022-05-27 青岛海之林生物科技开发有限公司 一种脂溶性藻酸乙酯及其制备方法与应用
CN115850533B (zh) * 2022-09-28 2023-07-21 青岛格诚经纬生物科技有限公司 一种海藻酸材料及其制备方法、应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3640741A (en) * 1970-02-24 1972-02-08 Hollister Inc Composition containing gel
JPS5416979B2 (hu) * 1972-01-08 1979-06-26
US4401456A (en) * 1980-01-09 1983-08-30 The United States Of America As Represented By The Secretary Of Agriculture Controlled release of bioactive materials using alginate gel beads
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
US4744933A (en) * 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US5147861A (en) * 1986-06-30 1992-09-15 Fidia S.P.A. Esters of alginic acid
JPS645460A (en) * 1987-06-29 1989-01-10 Sanei Kagaku Kogyo Kk Production of delaying gelatinous material
JPH07503943A (ja) * 1991-10-29 1995-04-27 クローバー　コンソリデイテッド，リミテッド 封入及び薬剤放出に有用な架橋性の多糖類、ポリカチオン及び脂質
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB2275686B (en) * 1993-03-03 1997-04-30 Johnson & Johnson Medical Swellable wound dressing materials
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
JPH10503179A (ja) * 1994-06-24 1998-03-24 イミュネックス・コーポレーション 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法
US5660859A (en) * 1994-12-29 1997-08-26 Mcneil-Ppc, Inc. Gelling agent for polyethylene glycol
WO1997015322A1 (en) * 1995-10-25 1997-05-01 The Regents Of The University Of California Methods for restoring or enhancing reproductive function in reproductively impaired hosts
JP2000505791A (ja) * 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EA199901013A1 (ru) * 1997-05-16 2000-06-26 Амген Инк. Гели пролонгированного действия
GB2339442B (en) * 1998-07-09 2002-06-05 Smith International Downhole tension swivel sub

Also Published As

Publication number Publication date
CN1309556A (zh) 2001-08-22
AU3993999A (en) 1999-12-06
BR9910553A (pt) 2001-01-30
EP1079811A1 (en) 2001-03-07
CA2331446C (en) 2004-03-16
YU69400A (sh) 2003-02-28
NO20005564D0 (no) 2000-11-03
CA2331446A1 (en) 1999-11-25
PL344337A1 (en) 2001-11-05
CY1105944T1 (el) 2011-04-06
EP1079811B1 (en) 2006-10-25
JP2002515419A (ja) 2002-05-28
NZ507943A (en) 2003-08-29
BG104943A (en) 2001-07-31
WO1999059549A1 (en) 1999-11-25
HUP0101895A3 (en) 2004-01-28
SK16752000A3 (sk) 2001-09-11
EA003670B1 (ru) 2003-08-28
US20020168406A1 (en) 2002-11-14
EA200001200A1 (ru) 2001-04-23
ES2275341T3 (es) 2007-06-01
DE69933763D1 (de) 2006-12-07
DK1079811T3 (da) 2007-02-26
ATE343378T1 (de) 2006-11-15
RS49841B (sr) 2008-08-07
US6432449B1 (en) 2002-08-13
NO20005564L (no) 2001-01-18
PT1079811E (pt) 2007-01-31
ZA200006299B (en) 2001-05-30
DE69933763T2 (de) 2007-10-04
IL139617A0 (en) 2002-02-10
KR20010025023A (ko) 2001-03-26
PL199499B1 (pl) 2008-09-30
BG65397B1 (bg) 2008-06-30

Similar Documents

Publication Publication Date Title
HUP0101895A2 (hu) Biológiailag lebontható, tartós felszabadulású alginát gélek
Lee et al. Controlled degradation of hydrogels using multi-functional cross-linking molecules
ES2354699T3 (es) Gel reticulado biocompatible.
Tsanaktsidou et al. On the synthesis and characterization of biofunctional hyaluronic acid based injectable hydrogels for the repair of cartilage lesions
ES2392061T3 (es) Matriz que comprende un esqueleto proteico de origen natural reticulado
DE60042325D1 (de) Iniezierbare hyaluronat-sulphatierte polysaccharid konjugate
EP3485919B1 (en) Preparation and/or formulation of proteins cross-linked with polysaccharides
DE602004028455D1 (de) Vernetzte polysaccharidzusammensetzung
DK0783285T3 (da) Resorberbar, vaskulær sårforbinding
DE69728678D1 (de) Hydrokolloid-wundgel
DK1028753T3 (da) Indgivelse af poly(ethylenglycol)-konjugerede molekyler fra nedbrydellige hydrogeler
YU67003A (sh) Nosac sa cvrstim fibrinogenom i cvrstim trombinom
JP2009120855A (ja) アルギネートまたは修飾アルギネートのようなポリサッカライドを含むポリマー
DK1019446T4 (da) Nedbrydelige poly(ethylenglycol)hydrogeler med styret halveringstid og prækursorer dertil
ATE206441T1 (de) Block- und pfropfcopolymere und dazu gehöriges verfahren
IL93166A0 (en) Cross-linked hydrogels and their use as wound dressings
MX2009002653A (es) Derivados de acido hialuronico obtenidos via reticulacion de "quimica modular".
HUT67479A (en) Process for producing cellulose-containing cereal extracts
Hoque et al. Interaction chemistry of functional groups for natural biopolymer-based hydrogel design
HK1068356A1 (en) Hyperbranched amylopectin for use in methods for surgical or therapeutic treatment of mammals or in diagnostic methods
ID26841A (id) Pati berfluiditas sagu dan penggunannya
BR9812774A (pt) Corpos formados para uso como implantes em medicina humana e método para a produção de tais corpos formados
EP0838224A2 (en) Polymer-drug conjugates with an enzyme cleavable linker
DE60024580D1 (de) Derivatisierte reduzierte malto-oligosaccharide
JP6939607B2 (ja) 組成物およびその用途

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees